No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SGRY Surgery Partners
- 24.540
- -0.090-0.37%
Trading May 2 12:55 ET
3.12BMarket Cap-272666P/E (TTM)
25.030High24.440Low195.66KVolume25.030Open24.630Pre Close4.82MTurnover0.26%Turnover RatioLossP/E (Static)127.10MShares45.79052wk High1.57P/B1.85BFloat Cap22.05052wk Low--Dividend TTM75.59MShs Float69.580Historical High--Div YieldTTM2.40%Amplitude4.000Historical Low24.620Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
While Shareholders of Surgery Partners (NASDAQ:SGRY) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate
While Surgery Partners, Inc. (NASDAQ:SGRY) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 24% in the last quarter. But
Express News | Benchmark Reiterates Buy on Surgery Partners, Maintains $50 Price Target
Should You Invest in Surgery Partners (SGRY)?
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details
BRENTWOOD, Tenn., April 18, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the
SGRY Vs. DOCS: Which Stock Should Value Investors Buy Now?
Express News | Surgery Partners Inc : Mizuho Cuts Target Price to $35 From $42
Comments
Surgery Partners' historical ROCE trend doesn't indicate potential for future multi-bagger status. Persistent low return on capital from its investments makes it unlikely to be a multi-bagger.
Returns On Capital At Surgery Partners (NASDAQ:SGRY) Have Hit The Brakes 1
Surgery Partners' high P/S ratio, despite industry-standard revenue forecasts, could risk shareholders' investments and potential investors may pay an unnecessary premium. This may be due to bullish sentiment, which could lead to disappointment if the P/S falls in line with the growth outlook.
Given Surgery Partners' current ROCE trends, it is not seen as a potential high-yield investment. Despite the stock's impressive performance in past years, if current underlying trends continue, the odds of it being a multi-bagger from here is slim.
ColumnsTop upgrades and downgrades on 6/15: SPOT, SNOW, CLR, CMTL and more
Upgrades
• $Arcos Dorados(ARCO.US$ : Bradesco BBI Upgrades to Outperform from Neutral - PT $12
• $Armstrong World Industries(AWI.US$ : Loop Capital Upgrades to Buy from Hold - PT $95
• $Cullen/Frost Bankers(CFR.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $155 (from $143)
• $Digital Realty Trust Inc(DLR.US$ : Deutsche Bank Upgrades to Buy from Hold - PT $144 (from $150)
• $Liberty Formula One-A(FWONA.US$ : Mor...
• $Arcos Dorados(ARCO.US$ : Bradesco BBI Upgrades to Outperform from Neutral - PT $12
• $Armstrong World Industries(AWI.US$ : Loop Capital Upgrades to Buy from Hold - PT $95
• $Cullen/Frost Bankers(CFR.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $155 (from $143)
• $Digital Realty Trust Inc(DLR.US$ : Deutsche Bank Upgrades to Buy from Hold - PT $144 (from $150)
• $Liberty Formula One-A(FWONA.US$ : Mor...
12
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg